64744 Federal Register / Vol. 75, No. 202 / Wednesday, October 20, 2010 / Notices 

the Correction to Notice of Application 

pertaining to Rhodes Technologies, 72 

FR 3417 (2007), comments and requests 

for hearings on applications to import 

narcotic raw material are not 

appropriate. 

Any bulk manufacturer who is 

presently, or is applying to be, 

registered with DEA to manufacture 

such basic classes of controlled 

substances listed in schedule I or II, 

which fall under the authority of section 

1002(a)(2)(B) of the Act (21 U.S.C. 

952(a)(2)(B)) may, in the circumstances 

set forth in 21 U.S.C. 958(i), file 

comments or objections to the issuance 

of the proposed registration and may, at 

the same time, file a written request for 

a hearing on such application pursuant 

to 21 CFR 1301.43 and in such form as 

prescribed by 21 CFR 1316.47. 

Any such comments or objections 

should be addressed, in quintuplicate, 

to the Drug Enforcement 

Administration, Office of Diversion 

Control, Federal Register Representative 

(ODL), 8701 Morrissette Drive, 

Springfield, Virginia 22152; and must be 

filed no later than November 19, 2010. 

This procedure is to be conducted 

simultaneously with, and independent 

of, the procedures described in 21 CFR 

1301.34(b), (c), (d), (e), and (f). As noted 

in a previous notice published in the 

Federal Register on September 23, 1975, 

(40 FR 43745), all applicants for 

registration to import a basic classes of 

any controlled substances in schedule I 

or II are, and will continue to be, 

required to demonstrate to the Deputy 

Assistant Administrator, Office of 

Diversion Control, Drug Enforcement 

Administration, that the requirements 

for such registration pursuant to 21 

U.S.C. 958(a); 21 U.S.C. 823(a); and 21 

CFR § 1301.34(b), (c), (d), (e), and (f) are 

satisfied. 

Dated: October 8, 2010. 

Joseph T. Rannazzisi, 

Deputy Assistant Administrator, Office of 

Diversion Control, Drug Enforcement 

Administration. 

[FR Doc. 2010–26454 Filed 10–19–10; 8:45 am] 

BILLING CODE 4410–09–P 

DEPARTMENT OF JUSTICE 

Drug Enforcement Administration 

Importer of Controlled Substances; 

Notice of Application 

Pursuant to 21 U.S.C. 958(i), the 

Attorney General shall, prior to issuing 

a registration under this section to a 

bulk manufacturer of a controlled 

substance in schedule I or II, and prior 

to issuing a regulation under 21 U.S.C. 

952(a)(2) authorizing the importation of 

such a substance, provide 

manufacturers holding registrations for 

the bulk manufacture of the substance 

an opportunity for a hearing. 

Therefore, in accordance with 21 CFR 

1301.34(a), this is notice that on 

September 15, 2010, Hospira Inc., 1776 

North Centennial Drive, McPherson, 

Kansas 67460–1247, made application 

by renewal to the Drug Enforcement 

Administration (DEA) to be registered as 

an importer of Remifentanil (9739), a 

basic class of controlled substance listed 

in schedule II. 

The company plans to import 

Remifentanil for use in dosage form 

manufacturing. 

Any bulk manufacturer who is 

presently, or is applying to be, 

registered with DEA to manufacture 

such basic class of controlled substance 

may file comments or objections to the 

issuance of the proposed registration 

and may, at the same time, file a written 

request for a hearing on such 

application pursuant to 21 CFR 1301.43 

and in such form as prescribed by 21 

CFR 1316.47. 

Any such comments or objections 

should be addressed, in quintuplicate, 

to the Drug Enforcement 

Administration, Office of Diversion 

Control, Federal Register Representative 

(ODL), 8701 Morrissette Drive, 

Springfield, Virginia 22152; and must be 

filed no later than November 22, 2010. 

This procedure is to be conducted 

simultaneously with, and independent 

of, the procedures described in 21 CFR 

1301.34(b), (c), (d), (e), and (f). As noted 

in a previous notice published in the 

Federal Register on September 23, 1975, 

(40 FR 43745), all applicants for 

registration to import a basic class of 

any controlled substance in schedule I 

or II are, and will continue to be, 

required to demonstrate to the Deputy 

Assistant Administrator, Office of 

Diversion Control, Drug Enforcement 

Administration, that the requirements 

for such registration pursuant to 21 

U.S.C. 958(a); 21 U.S.C. 823(a); and 21 

CFR 1301.34(b), (c), (d), (e), and (f) are 

satisfied. 

Dated: October 8, 2010. 

Joseph T. Rannazzisi, 

Deputy Assistant Administrator, Office of 

Diversion Control, Drug Enforcement 

Administration. 

[FR Doc. 2010–26445 Filed 10–19–10; 8:45 am] 

BILLING CODE 4410–09–P 

DEPARTMENT OF JUSTICE 

Drug Enforcement Administration 

Manufacturer of Controlled 

Substances; Notice of Application 

Pursuant to § 1301.33(a) of Title 21 of 

the Code of Federal Regulations (CFR), 

this is notice that on August 20, 2010, 

Cayman Chemical Company, 1180 East 

Ellsworth Road, Ann Arbor, Michigan 

48108, made application by renewal to 

the Drug Enforcement Administration 

(DEA) as a bulk manufacturer of the 

basic classes of controlled substances 

listed in schedule I: 

Drug Schedule 

Marihuana (7360) ......................... I 

Tetrahydrocannabinols (7370) ..... I 

The company plans to manufacture 

small quantities of marihuana 

derivatives for research purposes. In 

reference to drug code 7360 

(Marihuana), the company plans to bulk 

manufacture cannabidiol. In reference to 

drug code 7370 

(Tetrahydrocannabinols), the company 

will manufacture a synthetic THC. No 

other activity for this drug code is 

authorized for registration. 

Any other such applicant, and any 

person who is presently registered with 

DEA to manufacture such substances, 

may file comments or objections to the 

issuance of the proposed registration 

pursuant to 21 CFR 1301.33(a). 

Any such written comments or 

objections should be addressed, in 

quintuplicate, to the Drug Enforcement 

Administration, Office of Diversion 

Control, Federal Register Representative 

(ODL), 8701 Morrissette Drive, 

Springfield, Virginia 22152; and must be 

filed no later than December 20, 2010. 

Dated: October 8, 2010. 

Joseph T. Rannazzisi, 

Deputy Assistant Administrator, Office of 

Diversion Control, Drug Enforcement 

Administration. 

[FR Doc. 2010–26468 Filed 10–19–10; 8:45 am] 

BILLING CODE 4410–09–P 

DEPARTMENT OF JUSTICE 

Drug Enforcement Administration 

Manufacturer of Controlled 

Substances; Notice of Application 

Pursuant to § 1301.33(a) of Title 21 of 

the Code of Federal Regulations (CFR), 

this is notice that on September 14, 

2010, GE Healthcare, 3350 North Ridge 

Avenue, Arlington Heights, Illinois 

60004–1412, made application by 


emcdonald on DSK2BSOYB1PROD with NOTICES
Federal Register / Vol. 75, No. 202 / Wednesday, October 20, 2010 / Notices 64745 

renewal to the Drug Enforcement 

Administration (DEA) as a bulk 

manufacturer of Cocaine (9041), a basic 

class of controlled substance listed in 

schedule II. 

The company plans to manufacture a 

radioactive product used in diagnostic 

imaging in the diagnosis of Parkinson’s 

Disease and for manufacture in bulk for 

investigational new drug (IND) 

submission and clinical trials. 

Any other such applicant, and any 

person who is presently registered with 

DEA to manufacture such a substance, 

may file comments or objections to the 

issuance of the proposed registration 

pursuant to 21 CFR 1301.33(a). 

Any such written comments or 

objections should be addressed, in 

quintuplicate, to the Drug Enforcement 

Administration, Office of Diversion 

Control, Federal Register Representative 

(ODL), 8701 Morrissette Drive, 

Springfield, VA 22152; and must be 

filed no later than December 20, 2010. 

Dated: October 8, 2010. 

Joseph T. Rannazzisi, 

Deputy Assistant Administrator, Office of 

Diversion Control, Drug Enforcement 

Administration. 

[FR Doc. 2010–26443 Filed 10–19–10; 8:45 am] 

BILLING CODE 4410–09–P 

DEPARTMENT OF JUSTICE 

Drug Enforcement Administration 

Manufacturer of Controlled 

Substances; Notice of Application 

Pursuant to § 1301.33(a) of Title 21 of 

the Code of Federal Regulations (CFR), 

this is notice that on July 12, 2010, 

Noramco Inc., 500 Swedes Landing 

Road, Wilmington, Delaware 19801– 

4417, made application by renewal to 

the Drug Enforcement Administration 

(DEA) as a bulk manufacturer of the 

basic classes of controlled substances 

listed in schedules I and II: 

Drug Schedule 

Codeine-N-oxide (9053) ............... I 

Dihydromorphine (9145) ............... I 

Morphine-N-oxide (9307) ............. I 

Methylphenidate (1724) ................ II 

Codeine (9050) ............................. II 

Dihydrocodeine (9120) ................. II 

Oxycodone (9143) ........................ II 

Hydromorphone (9150) ................ II 

Hydrocodone (9193) ..................... II 

Morphine (9300) ........................... II 

Thebaine (9333) ........................... II 

Opium extracts (9610) .................. II 

Opium fluid extract (9620) ............ II 

Opium tincture (9630) .................. II 

Opium, powdered (9639) ............. II 

Opium, granulated (9640) ............ II 

Oxymorphone (9652) ................... II 

Drug Schedule 

Noroxymorphone (9668) .............. II 

Tapentadol (9780) ........................ II 

The company plans to manufacture 

the listed controlled substances in bulk 

for distribution to its customers. 

Any other such applicant, and any 

person who is presently registered with 

DEA to manufacture such substance, 

may file comments or objections to the 

issuance of the proposed registration 

pursuant to 21 CFR 1301.33(a). 

Any such written comments or 

objections should be addressed, in 

quintuplicate, to the Drug Enforcement 

Administrator, Office of Diversion 

Control, Federal Register Representative 

(ODL), 8701 Morrissette Drive, 

Springfield, Virginia 22152; and must be 

filed no later than December 20, 2010. 

Dated: October 8, 2010. 

Joseph T. Rannazzisi, 

Deputy Assistant Administrator, Office of 

Diversion Control, Drug Enforcement 

Administration. 

[FR Doc. 2010–26456 Filed 10–19–10; 8:45 am] 

BILLING CODE 4410–09–P 

DEPARTMENT OF JUSTICE 

Drug Enforcement Administration 

Manufacturer of Controlled 

Substances; Notice of Application 

Pursuant to § 1301.33(a) of Title 21 of 

the Code of Federal Regulations (CFR), 

this is notice that on July 7, 2010, 

National Center for Natural Products 

Research—NIDA MProject, University of 

Mississippi, 135 Coy Waller Lab 

Complex, University, Mississippi 38677, 

made application by renewal to the 

Drug Enforcement Administration 

(DEA) to be registered as a bulk 

manufacturer of the basic classes of 

controlled substances listed in schedule 

I: 

Drug Schedule 

Marihuana (7360) ......................... I 

Tetrahydrocannabinols (7370) ..... I 

The company plans to cultivate 

marihuana for the National Institute on 

Drug Abuse for research approved by 

the Department of Health and Human 

Services. 

Any other such applicant, and any 

person who is presently registered with 

DEA to manufacture such substances, 

may file comments or objections to the 

issuance of the proposed registration 

pursuant to 21 CFR 1301.33(a). 

Any such written comments or 

objections should be addressed, in 

quintuplicate, to the Drug Enforcement 

Administration, Office of Diversion 

Control, Federal Register Representative 

(ODL), 8701 Morrissette Drive, 

Springfield, Virginia 22152; and must be 

filed no later than December 20, 2010. 

Dated: October 8, 2010. 

Joseph T. Rannazzisi, 

Deputy Assistant Administrator, Office of 

Diversion Control, Drug Enforcement 

Administration. 

[FR Doc. 2010–26450 Filed 10–19–10; 8:45 am] 

BILLING CODE 4410–09–P 

DEPARTMENT OF JUSTICE 

Drug Enforcement Administration 

Manufacturer of Controlled 

Substances; Notice of Application 

Pursuant to § 1301.33(a) of Title 21 of 

the Code of Federal Regulations (CFR), 

this is notice that on August 20, 2010, 

Halo Pharmaceutical Inc., 30 North 

Jefferson Road, Whippany, New Jersey 

07981, made application by renewal to 

the Drug Enforcement Administration 

(DEA) to be registered as a bulk 

manufacturer of the basic classes of 

controlled substances listed in 

schedules I and II: 

Drug Schedule 

Dihydromorphine (9145) ............... I 

Hydromorphone (9150) ................ II 

Dihydromorphine is an intermediate 

in the manufacture of Hydromorphone 

and is not for commercial distribution. 

The company plans to manufacture 

Hydromorphone HCL for sale to other 

manufacturers and for the manufacture 

of other controlled substance dosage 

units for distribution to its customers. 

Any other such applicant, and any 

person who is presently registered with 

DEA to manufacture such substances, 

may file comments or objections to the 

issuance of the proposed registration 

pursuant to 21 CFR 1301.33(a). 

Any such written comments or 

objections should be addressed, in 

quintuplicate, to the Drug Enforcement 

Administration, Office of Diversion 

Control, Federal Register Representative 

(ODL), 8701 Morrissette Drive, 

Springfield, Virginia 22152; and must be 

filed no later than December 20, 2010. 

Dated: October 8, 2010. 

Joseph T. Rannazzisi, 

Deputy Assistant Administrator, Office of 

Diversion Control, Drug Enforcement 

Administration. 

[FR Doc. 2010–26469 Filed 10–19–10; 8:45 am] 

BILLING CODE 4410–09–P 


emcdonald on DSK2BSOYB1PROD with NOTICES